Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital of Xi'an Jiaotong UniversityActive in the last 2 years

Ruiqi Cao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9160-0911; OpenAlex author ID A5102960235. Sources: OpenAlex.

Their work

Papers
3 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
12
Papers, trials and grants by year

2024: 1 paper · 2025: 2 papers

Papers 3

  1. Elevated SREBP1 accelerates the initiation and growth of pancreatic cancer by targeting SOX9. Co-author DOI 10.1186/s13062-025-00595-1↗
  2. Tobacco carcinogen NNK promotes pancreatic cancer proliferation via LINC00857/β-catenin. First author DOI 10.18332/tid/203455↗
  3. Pharmacological inhibition of SREBP1 suppresses pancreatic cancer growth via inducing GPX4-mediated ferroptosis. Co-author DOI 10.1016/j.cellsig.2024.111381↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qingyong Ma · 3 shared papers, 2024–2025 · strength 0.66
  2. Cancan Zhou · 3 shared papers, 2024–2025 · strength 0.66
  3. Jie Hao · 2 shared papers, 2025 · strength 0.45
  4. Weikun Qian · 2 shared papers, 2025 · strength 0.45
  5. Jiantao Mo · 2 shared papers, 2024–2025 · strength 0.44
  6. Zheng Wang · 2 shared papers, 2024–2025 · strength 0.44
  7. Zheng Wu · 2 shared papers, 2024–2025 · strength 0.43
  8. Shuai Wu · 1 shared paper, 2025 · strength 0.22
  9. Zeen Zhu · 1 shared paper, 2025 · strength 0.22
  10. Wunai Zhang · 1 shared paper, 2025 · strength 0.22
  11. Xuqi Li · 1 shared paper, 2025 · strength 0.22
  12. Wei Li · 1 shared paper, 2024 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.